Alexion PharmaceuticalsのQuick ratio
Alexion PharmaceuticalsのQuick ratioは何ですか。
Alexion Pharmaceuticals Inc.のQuick ratioは3.47です。
Quick ratioの定義は何ですか。
当座比率は、短期債務を即座に満たすために迅速な資産を使用する企業の能力を測定する流動性比率です。
The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.
NASDAQのセクタHealth CareにおけるQuick ratioの企業と比べるAlexion Pharmaceuticals
Alexion Pharmaceuticalsは何をしますか。
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticalsと類似のquick ratio
- Trevena IncのQuick ratioは3.46です。
- Aquis Exchange PLCのQuick ratioは3.46です。
- Inventiva SAのQuick ratioは3.46です。
- LynasのQuick ratioは3.46です。
- LynasのQuick ratioは3.46です。
- DermTechのQuick ratioは3.46です。
- Alexion PharmaceuticalsのQuick ratioは3.47です。
- Sing Tao NewsのQuick ratioは3.47です。
- Castlecap CapitalのQuick ratioは3.47です。
- MBIAのQuick ratioは3.47です。
- Wim PlastのQuick ratioは3.47です。
- SNL BearingsのQuick ratioは3.47です。
- ScienjoyのQuick ratioは3.47です。